Learn about Tessellate BIO and meet the team

About us

Tessellate BIO was founded to develop precision oncology approaches to treat cancers with high unmet need.

We are initially focusing on validated targets to address the group of cancers that depend on the alternative lengthening of telomeres (ALT) which can be detected with our proprietary companion diagnostic.

We are building an innovative pipeline by exploiting synthetic lethal targets in DNA damage response pathways and loss-of-function of tumor suppressors.

Tessellate BIO’s values are based on international collaborations and unifying approaches. Inspired by the tessellating works of M.C. Escher, we designed this image to represent our therapy’s journey from chromosome to patient.

Open the tabs
and meet the team.
Click on the images
to know more

Meet the team

Tessellate BIO was founded based on the research of two renowned scientists in the field of telomere biology, Professors Hilda Pickett and Claus Azzalin.

We have a driven multinational team of industry- and biotech-experienced R&D leaders and scientists.

The Tessellate BIO team is supported by a scientific advisory board of internationally recognized leaders in cancer research, synthetic lethality, DNA damage response, alternative lengthening of telomeres, clinical development of precision medicines, and a board of directors experienced in the management of early-stage life science companies.

Leadership Team

Andree Blaukat

CEO

Andrew Lightfoot

COO

Jürgen Moll

CSO

Katie Chapman

Head of Discovery Research

Laurent Rigoreau

Head of Medicinal Chemistry

Joris Schuurmans

Head of Diagnostics

Asiya Giniatullina

Head of Operations

Lee Larcombe

Head of Bioinformatics

Board of Directors

Eliot Forster

Chair of the Board

Claus Azzalin

Co-Founder

Andree Blaukat

CEO

Daniela Couto

BioGeneration Ventures

Rogier Rooswinkel

Forbion

Keno Gutierrez

BioGeneration Ventures

Founders

Professor Hilda Pickett

Professor Claus Azzalin

Leadership Team

Andree Blaukat

CEO

Andrew Lightfoot

COO

Jürgen Moll

CSO

Katie Chapman

Head of Discovery Research

Laurent Rigoreau

Head of Medicinal Chemistry

Joris Schuurmans

Head of Diagnostics

Asiya Giniatullina

Head of Operations

Lee Larcombe

Head of Bioinformatics

Board of Directors

Eliot Forster

Chair of the Board

Claus Azzalin

Co-Founder

Andree Blaukat

CEO

Daniela Couto

BioGeneration Ventures

Rogier Rooswinkel

Forbion

Keno Gutierrez

BioGeneration Ventures

Scientific Advisory Board

Professor Roger Reddel

Chair

Professor Hilda Pickett

Co-Founder

Professor Claus Azzalin

Co-Founder

Professor Christopher Lord

Professor René Bernards

Professor Andrew Deans

Professor George Demetri

Professor Giulio Draetta

Professor Timothy Yap

Leadership Team

Andree Blaukat

CEO

Andrew Lightfoot

COO

Jürgen Moll

CSO

Katie Chapman

Head of Discovery Research

Laurent Rigoreau

Head of Medicinal Chemistry

Joris Schuurmans

Head of Diagnostics

Asiya Giniatullina

Head of Operations

Lee Larcombe

Head of Bioinformatics

Board of Directors

Eliot Forster

Chair of the Board

Claus Azzalin

Co-Founder

Andree Blaukat

CEO

Daniela Couto

BioGeneration Ventures

Rogier Rooswinkel

Forbion

Keno Gutierrez

BioGeneration Ventures

Scientific Advisory Board

Professor Roger Reddel

Chair

Professor Hilda Pickett

Co-Founder

Professor Claus Azzalin

Co-Founder

Professor Christopher Lord

Professor René Bernards

Professor Andrew Deans

Professor George Demetri

Professor Giulio Draetta

Professor Timothy Yap

Founders

Professor Hilda Pickett

Professor Claus Azzalin

Investors

Would you like to know more?

Gooimeer 2-35 | 1411 DC Naarden | The_Netherlands
Privacy PolicyTerms & ConditionsCookie policy
Tessellate Bio is a registered trademark of Tessellate Bio BV
Copyright ©2024 TessellateBIO BV All rights reserved.